• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Draper, Pfizer ink ‘organ-on-a-chip’ deal

December 20, 2016 By Sarah Faulkner

Draper, Pfizer ink 'organ-on-a-chip' dealDraper said today that it inked a 3-year collaboration deal with Pfizer (NYSE:PFE) to develop Draper’s microphysiological system technology. The ‘organ-on-a-chip’ system is designed to improve preclinical safety and model diseases more effectively.

The Cambridge, Mass.-based company’s miniature organ model enables researchers to measure tissue function and test potential new drug candidates. Draper and Pfizer will collaborate on 3 microphysiological systems – liver, vascular and gastrointestinal organs.

The models can be easily integrated with existing lab screening tools, according to the companies, and could 1 day help pharmaceutical companies by providing accurate results more efficiently than conventional methods.

“We’re engineering an environment that encourages cells to function in vitro as they would in specific human organs in vivo,” Draper Biomedical Solutions’ Joseph Charest said in prepared remarks. “We believe that the real value proposition of Draper’s technology is that, in addition to creating the optimal environment for cell function, our sensing technology measures the function of the cells directly and in real-time while our format ensures the system will scale to high levels of throughput.”

“If we’re successful, this technology may enable new patient therapies that are safer and more precisely tailored to a disease, a population or a specific patient,” Draper’s VP of commercial solutions Tara Clark added. “We hope to demonstrate that MPS technology has the potential to reduce risks and costs, and improve translation into the clinic.”

“We believe that utilizing Draper’s MPS technology has the potential to help us overcome 1 of the challenges of drug discovery, which is translation from in vitro to in vivo and from preclinical to clinical,” Pfizer’s VP of drug safety research & development John Burkhardt said. “Finding a more efficient way to bridge the translation gap would enable us to humanize the drug discovery process and reduce dependence on other 2-dimensional models, and ultimately to more quickly bring new medicines to patients who need them.”

Filed Under: Featured, Pharmaceuticals, Preclinical Trials, Wall Street Beat Tagged With: Draper, Pfizer Inc.

IN CASE YOU MISSED IT

  • Surmodics’ DCB shown non-inferior to Medtronic’s In.Pact Admiral
  • How continuous glucose monitors have transformed the diabetes landscape
  • Biden’s COVID-19 response will make manufacturers busy
  • Mylan must face EpiPen racketeering lawsuit
  • EmblemHealth to provide coverage for Senseonics’ Eversense CGM

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS